Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
Biotechnology company developing gene therapies and genome editing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Engineered immune cells aim to trick the body into accepting a new kidney
Disease control CompletedThis trial tests a new cell therapy called TX200-TR101 in people who receive a kidney from a living donor. The therapy is made from the patient's own immune cells, which are genetically modified to help the body accept the donated kidney instead of rejecting it. The study focuses…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One-Time gene therapy could change fabry disease treatment
Disease control CompletedThis trial tested a new gene therapy called ST-920 for Fabry disease, a rare genetic condition. The therapy uses a harmless virus to deliver a working gene that helps the body produce an enzyme it's missing. 36 adults with Fabry disease received a single intravenous dose and were…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene-Editing hope: could BIVV003 free sickle cell patients from pain crises?
Disease control CompletedThis early-phase trial tested a new gene therapy called BIVV003 in 7 adults with severe sickle cell disease. The treatment uses the patient's own stem cells, which are gene-edited in a lab and then infused back after chemotherapy. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC